In RA patients treated with TNF-α–blocking agents, levels of serum VE-cadherin significantly correlated with C-reactive protein (CRP), a marker of inflammation and disease activity, and were lower in patients whose CRP fell in response to therapy (47). This evidence concerns the gene TNF and rheumatoid arthritis.